OncoCyte Corp (OCX)
2.66
-0.12
(-4.30%)
USD |
NASDAQ |
May 03, 16:00
2.69
+0.03
(+1.13%)
Pre-Market: 20:00
OncoCyte Profit Margin (Quarterly): -5.09K% for Dec. 31, 2023
Profit Margin (Quarterly) Chart
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -5.09K% |
| September 30, 2023 | -1.51K% |
| June 30, 2023 | -1.80K% |
| March 31, 2023 | |
| December 31, 2022 | -16.42K% |
| September 30, 2022 | -13.93K% |
| June 30, 2022 | -3.50K% |
| March 31, 2022 | -2.71K% |
| Date | Value |
|---|---|
| December 31, 2021 | |
| September 30, 2021 | -1.40K% |
| June 30, 2021 | -516.9% |
| March 31, 2021 | -348.7% |
| December 31, 2020 | -1.25K% |
| September 30, 2020 | -1.22K% |
| June 30, 2020 | -6.37K% |
| March 31, 2020 | -48.32K% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
-48.32K%
Minimum
Mar 2020
-348.7%
Maximum
Mar 2021
-7.46K%
Average
-2.25K%
Median
Profit Margin (Quarterly) Benchmarks
| Fonar Corp | 14.81% |
| XWELL Inc | -88.94% |
| ProPhase Labs Inc | -250.1% |
| Applied DNA Sciences Inc | -124.0% |
| Veracyte Inc | -28.81% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | -79.90% |
| Return on Assets | -32.54% |
| Return on Invested Capital | -79.90% |
| Gross Profit Margin (Quarterly) | -37.26% |
| Operating Margin (Quarterly) | -1.61K% |
| Return on Net Operating Assets | -41.52% |